A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase
about
sameAs
H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signalingThe HRASLS (PLA/AT) subfamily of enzymes1H, 13C, and 15N resonance assignments of the N-terminal domain of human TIG3Structural and functional characterization of tumor suppressors TIG3 and H-REV107Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinomaA novel transglutaminase activator forms a complex with type 1 transglutaminaseTIG3 tumor suppressor-dependent organelle redistribution and apoptosis in skin cancer cellsInduction of apoptosis by the retinoid inducible growth regulator RIG1 depends on the NC motif in HtTA cervical cancer cells.Phospholipase A/Acyltransferase enzyme activity of H-rev107 inhibits the H-RAS signaling pathwayTransglutaminase regulation of cell function.Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.TIG3: an important regulator of keratinocyte proliferation and survival.Type I transglutaminase accumulation in the endoplasmic reticulum may be an underlying cause of autosomal recessive congenital ichthyosis.RIG-I- and MDA5-initiated innate immunity linked with adaptive immunity accelerates beta-cell death in fulminant type 1 diabetesTIG3: a regulator of type I transglutaminase activity in epidermis.Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cellsH-rev107 Regulates Cytochrome P450 Reductase Activity and Increases Lipid Accumulation.Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.TIG3 interaction at the centrosome alters microtubule distribution and centrosome function.Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies.H-rev107 regulates prostaglandin D2 synthase-mediated suppression of cellular invasion in testicular cancer cells.Pericentrosomal localization of the TIG3 tumor suppressor requires an N-terminal hydrophilic region motif.Suppression of the tumorigenic phenotype in human oral squamous cell carcinoma cells by an ethanol extract derived from freeze-dried black raspberries.Expression of the class II tumor suppressor gene RIG1 is directly regulated by p53 tumor suppressor in cancer cell lines.Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.Irradiated human dermal fibroblasts are as efficient as mouse fibroblasts as a feeder layer to improve human epidermal cell culture lifespan.Hoxb13 up-regulates transglutaminase activity and drives terminal differentiation in an epidermal organotypic model.High expression of TIG3 predicts poor survival in patients with primary glioblastoma.
P2860
Q24671049-AE0C8015-5F35-4D87-A617-3A1F7A1F67BBQ26778781-4F0BE6EB-E72A-404E-9C92-1A974A13282CQ27676949-C0BB0F70-8064-410E-864C-783001D83289Q27700199-8D19DE14-E76D-479E-B419-5A80A89776ECQ28237677-F50BBD6A-8E8D-4ACC-B056-044CF621FBEEQ28246458-A45502F1-998F-46E7-834B-9FFCBA94266BQ28476596-B82FECC7-21DD-4DAD-AFF2-BDEEAC3E39DEQ33412885-6AF81665-A96B-4536-9DE1-276DFA52EB81Q33576902-74E04FAA-956A-426C-A5A9-05753ACF9422Q33707936-0DDB6E0F-8E0C-4DEB-8F1F-3CF00E9CF649Q33728989-7020A371-5FB7-4648-891B-99FB06B4EE2BQ33756781-43AB5B89-A402-4778-8AAE-8565B7002F22Q34181509-55112F99-3606-466D-8666-5EC7D5EAC1DAQ34615467-6692CDC2-E893-487D-9752-8095C26A7CD8Q35072914-F9EED9C5-3848-4254-8651-4B194883894FQ35349515-2C89E4A3-DDF1-42F1-82EE-EBD69F0F5A06Q35779396-88531254-4D68-4D8A-8BED-54588FB40E0EQ35858675-0A360F4C-8A46-48DE-B6B4-F1CB33A39075Q36111264-3A623BD1-E0EF-413A-B2CD-14806CC30951Q36588457-0974508D-F992-400B-9508-B03F227BA136Q36891854-98C97322-E195-45B7-BD79-A3AF98922D59Q37707167-D60AD492-BE19-4F92-97BD-D3BEDC3ACB1DQ38590426-C546F497-7DED-4D82-8E15-7D6ADAF7D255Q39344280-C30A3DBF-44B3-4078-99DF-B6DB3746B8BDQ39447519-D650FB0C-A98C-44C3-A9A0-10C58C75FDC5Q40043311-98ED2B13-8EC6-494D-B693-6A0AE984393BQ40407557-DB083FDB-289C-498B-AB2B-E46BBD352E3BQ50929840-CA324031-3DF0-4073-BF24-7A6C9DC1209C
P2860
A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A novel tumor suppressor prote ...... ion of type I transglutaminase
@ast
A novel tumor suppressor prote ...... ion of type I transglutaminase
@en
A novel tumor suppressor prote ...... ion of type I transglutaminase
@nl
type
label
A novel tumor suppressor prote ...... ion of type I transglutaminase
@ast
A novel tumor suppressor prote ...... ion of type I transglutaminase
@en
A novel tumor suppressor prote ...... ion of type I transglutaminase
@nl
prefLabel
A novel tumor suppressor prote ...... ion of type I transglutaminase
@ast
A novel tumor suppressor prote ...... ion of type I transglutaminase
@en
A novel tumor suppressor prote ...... ion of type I transglutaminase
@nl
P2093
P2860
P356
P1476
A novel tumor suppressor prote ...... ion of type I transglutaminase
@en
P2093
Anne Deucher
Ellen A Rorke
Michael T Sturniolo
Richard L Eckert
Roshantha A S Chandraratna
Tiffany Keepers
P2860
P304
48066-48073
P356
10.1074/JBC.M307215200
P407
P577
2003-08-19T00:00:00Z